Download presentation
Presentation is loading. Please wait.
Published byJesse Washington Modified over 6 years ago
1
Predictors of restenosis in the use of helical interwoven nitinol stents to treat femoropopliteal occlusive disease Yiu Che Chan, MBBS, MD, FRCS, Stephen W. Cheng, MBBS, MS, FRCS, Grace C. Cheung, MMedSc Journal of Vascular Surgery Volume 62, Issue 5, Pages (November 2015) DOI: /j.jvs Copyright © 2015 Society for Vascular Surgery Terms and Conditions
2
Fig 1 An angiogram shows (A) right popliteal artery stenosis with (B) angioplasty and (C) stenting. D, Anteroposterior and (E) lateral view plain radiographs show the Supera stent (IDEV Technologies, Inc/Abbott Laboratories, Inc, Webster, Tex). Journal of Vascular Surgery , DOI: ( /j.jvs ) Copyright © 2015 Society for Vascular Surgery Terms and Conditions
3
Fig 2 Kaplan-Meier curve shows overall primary patency rates, with error bars representing standard errors. Journal of Vascular Surgery , DOI: ( /j.jvs ) Copyright © 2015 Society for Vascular Surgery Terms and Conditions
4
Fig 3 The primary patency rate as analyzed by disease segment of the superficial femoral artery (SFA) or SFA with or without the popliteal artery. Journal of Vascular Surgery , DOI: ( /j.jvs ) Copyright © 2015 Society for Vascular Surgery Terms and Conditions
5
Fig 4 The primary patency rate as analyzed by indication of treatment for claudication vs critical ischemia/tissue loss. Journal of Vascular Surgery , DOI: ( /j.jvs ) Copyright © 2015 Society for Vascular Surgery Terms and Conditions
6
Fig 5 The primary patency rate as analyzed by patients who had 5-mm or 4-mm Supera stents (IDEV Technologies, Inc/Abbott Laboratories, Inc, Webster, Tex) implanted. Journal of Vascular Surgery , DOI: ( /j.jvs ) Copyright © 2015 Society for Vascular Surgery Terms and Conditions
Similar presentations
© 2024 SlidePlayer.com. Inc.
All rights reserved.